The NAACP and Singleton Schreiber are proud to announce an official partnership to investigate cases involving the recalled sickle cell medication Oxbryta (Voxelotor), aiming to secure justice and compensation for patients adversely affected by the drug's undisclosed safety risks.
Sickle cell disease predominantly impacts communities of color and poses significant health challenges to millions worldwide. Oxbryta, approved by the FDA in 2019 under accelerated conditions before full trials were completed, was intended to improve patient outcomes by normalizing red blood cell counts. However, troubling studies revealed that the drug carried severe potential side effects and long-term health impacts, including increased risks of vaso-occlusive crises and deaths. Pfizer, which acquired Oxbryta's original manufacturer Global Blood Therapeutics in 2022, withdrew the medication from the market in September 2024 due to these risks. By then, Oxbryta had been in use for nearly five years, long enough for significant harm to have already occurred.
"The NAACP has long been committed to protecting the health and safety of communities of color," said Derrick Johnson, president and CEO of the NAACP. "The troubling impacts of this medication and the circumstancessurrounding Oxbryta's approval and subsequent recall highlight the urgent need to hold corporations accountable when they bypass normal protocols and place profits over people's lives."
Singleton Schreiber is honored to serve as legal co-counsel alongside the NAACP, guiding affected patients through the complex legal process. Oxbryta cases are being filed as individual claims ensuring each patient's unique experience and health impacts are recognized.
"Too often, vulnerable communities suffer in silence when corporations fail to disclose critical safety information," said Letitia Johnson, Managing Partner of Singleton Schreiber's Southeastern Region. "By partnering with the NAACP, we are stronger in our fight to support sickle cell patients and their families, seeking the justice they deserve."
Individuals who took Oxbryta and suffered serious complications, including vaso-occlusive crises, strokes, or death, may be entitled to compensation. Even those who did not experience negative side effects are encouraged to come forward for better understanding of the impact of this medication.
Together, Singleton Schreiber and the NAACP are committed to amplifying awareness, providing legal support, and challenging the systemic issues that allowed these risks to go undisclosed for so long.